These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27458309)

  • 1. Industry-Academic Relationship in a New Era of Drug Discovery.
    Vallance P
    J Clin Oncol; 2016 Oct; 34(29):3570-3575. PubMed ID: 27458309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partnership between academia and industry for drug discovery in Alzheimer's disease.
    Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
    Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.
    Takebe T; Imai R; Ono S
    Clin Transl Sci; 2018 Nov; 11(6):597-606. PubMed ID: 29940695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials and tribulations: a personal view of interacting with pharmaceutical manufacturers.
    Scheifele DW
    Clin Invest Med; 1997 Jun; 20(3):188-92. PubMed ID: 9189650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical pipeline.
    Lowen T
    Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationships between academic institutions and industry in the life sciences--an industry survey.
    Blumenthal D; Causino N; Campbell E; Louis KS
    N Engl J Med; 1996 Feb; 334(6):368-73. PubMed ID: 8538709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open for collaboration: an academic platform for drug discovery and development at SciLifeLab.
    Arvidsson PI; Sandberg K; Forsberg-Nilsson K
    Drug Discov Today; 2016 Oct; 21(10):1690-1698. PubMed ID: 27373760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
    Wong EH; Yocca F; Smith MA; Lee CM
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1269-84. PubMed ID: 20716397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of PET radiopharmaceuticals at the academia-industry interface.
    Bernard-Gauthier V; Collier TL; Liang SH; Vasdev N
    Drug Discov Today Technol; 2017 Nov; 25():19-26. PubMed ID: 29233263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. University - industry collaborations: models, drivers and cultures.
    Ehrismann D; Patel D
    Swiss Med Wkly; 2015; 145():w14086. PubMed ID: 25658854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Academic drug discovery: current status and prospects.
    Everett JR
    Expert Opin Drug Discov; 2015; 10(9):937-44. PubMed ID: 26088126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HTS and hit finding in academia--from chemical genomics to drug discovery.
    Frearson JA; Collie IT
    Drug Discov Today; 2009 Dec; 14(23-24):1150-8. PubMed ID: 19793546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Academic partnerships 2014.
    Huggett B
    Nat Biotechnol; 2015 Apr; 33(4):333. PubMed ID: 25850049
    [No Abstract]   [Full Text] [Related]  

  • 17. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).
    Bruyere O; Kanis JA; Ibar-Abadie ME; Alsayed N; Brandi ML; Burlet N; Cahall DL; Chines A; Devogelaer JP; Dere W; Goel N; Hughes N; Kaufman JM; Korte S; Mitlak BH; Niese D; Rizzoli R; Rovati LC; Reginster JY
    Osteoporos Int; 2010 May; 21(5):713-22. PubMed ID: 20238101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
    Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
    Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies.
    Gardell SJ; Roth GP; Kelly DP
    J Cardiovasc Transl Res; 2010 Oct; 3(5):431-7. PubMed ID: 20625868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How academic labs can approach the drug discovery process as a way to synergize with big pharma.
    Loregian A; Palù G
    Trends Microbiol; 2013 Jun; 21(6):261-4. PubMed ID: 23731493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.